Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009

The Lancet Oncology

Volumn 10, Issue 11, 2009, Pages 1093-1101

  Kwong, Yok Lam ^a   Anderson, Benjamin O ^b   Advani, Ranjana ^c   Kim, Won Seog ^d   Levine, Alexandra M ^e   Lim, Soon Thye ^f  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Samsung Medical Center   (South Korea)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ASPARAGINASE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; STEROID; VINCRISTINE; VINDESINE;

ASIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FEBRILE NEUTROPENIA; HEALTH CARE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; NEUTROPENIA; NK T CELL LYMPHOMA; ONTOGENY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RESOURCE ALLOCATION; REVIEW; T CELL LYMPHOMA; TUMOR CLASSIFICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CONGRESSES AS TOPIC; DEVELOPING COUNTRIES; EVIDENCE-BASED MEDICINE; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOMA; LYMPHOMA, T-CELL; MEDICAL ONCOLOGY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 71249097862     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70265-7     Document Type: Review

References (61)

1. Anderson J.R., Armitage J.O., and Weisenburger D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9 (1998) 717-720
2. Au W.Y., Ma S.Y., Chim C.S., et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16 (2005) 206-214
3. Dogan A., Gaulard P., Jaffe E.S., Ralfkiaer E., and Muller-Hermelink H.K. Angioimmunoblastic T-cell lymphoma. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 309-311
4. Delsol G., Falini B., Muller-Hermelink H.K., et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 312-316
5. Mason D.Y., Harris N.L., Delsol G., et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 317-319
6. Pileri S.A., Weisenburger D.D., Sng I., et al. Peripheral T-cell lymphoma, not otherwise specified. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 306-308
7. Blom B., and Spits H. Development of human lymphoid cells. Annu Rev Immunol 24 (2006) 287-320
8. Jaffe E.S., Harris N.L., Stein H., Campo E., Pileri S.A., and Swerdlow S.H. Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 158-166
9. Isaacson P.G., Chott A., Ott G., and Stein H. Enteropathy-associated T-cell lymphoma. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 289-291
10. Ohshima K., Jaffe E.S., and Kikuchi M. Adult T-cell leukaemia/lymphoma. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 281-284
11. Gaulard P., Jaffe E.S., Krenacs L., and Macon W.R. Hepatosplenic T-cell lymphoma. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 292-293
12. Jaffe E.S., Gaulard P., Ralfkiaer E., Cerroni L., and Meijer C.J.L.M. Subcutaneous panniculiits-like T-cell lymphoma. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds) (2008), International Agency for Research on Cancer, Lyon, France 294-295
13. Kwong Y.L. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19 (2005) 2186-2194
14. Chan J.K.C., Quintanilla-Martinez L., Ferry J.A., and Peh S.C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 285-288
15. Chan J.K.C., Jaffe E.S., Ralfkiaer E., and Ko Y.H. Aggressive NK-cell leukaemia. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 276-277
16. Quintanilla-Martinez, Kimura H., and Jaffe E.S. EBV-positive T-cell lymphoproliferative disorders of childhood. In: Swerdlow S.H., Campo E., Harris N.L., et al. (Eds). WHO classification of tumours of haematopoietic and lymphoid tissues (2008), International Agency for Research on Cancer, Lyon, France 278-280
17. Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 113 8 suppl (2008) 2221-2243
18. Kako S., Izutsu K., Ota Y., et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18 (2007) 1685-1690
19. Khong P.L., Pang C.B., Liang R., Kwong Y.L., and Au W.Y. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 87 (2008) 613-621
20. Au W.Y., Pang A., Choy C., Chim C.S., and Kwong Y.L. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104 (2004) 243-249
21. Gascoyne R.D., Aoun P., Wu D., et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93 (1999) 3913-3921
22. Falini B., Pileri S., Zinzani P.L., et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93 (1999) 2697-2706
23. Ten Berge R.L., Oudejans J.J., Ossenkoppele G.J., et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 53 (2000) 445-450
24. Savage K.J., Harris N.L., Vose J.M., et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111 (2008) 5496-5504
25. Armitage J., Vose J., and Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26 (2008) 4124-4130
26. Mourad N., Mounier N., Briere J., et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111 (2008) 4463-4470
27. Gallamini A., Stelitano C., Calvi R., et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 103 (2004) 2474-2479
28. Armitage J.O., Greer J.P., Levine A.M., et al. Peripheral T-cell lymphoma. Cancer 63 (1989) 158-163
29. López-Guillermo A., Cid J., Salar A., et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol 9 (1998) 849-855
30. Tilly H., Lepage E., Coiffier B., et al., Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102 (2003) 4284-4289
31. Escalón M.P., Liu N.S., Yang Y., et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 103 (2005) 2091-2098
32. Pfreundschuh M., Trümper L., Kloess M., et al., German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104 (2004) 626-633
33. Pfreundschuh M., Trümper L., Kloess M., et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641
34. Hotta T., Shimakura Y., Ishizuka N., et al. Randomized phase 3 study of standard CHOP versus biweekly CHOP in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group study, JCOG9809. Proc Am Soc Clin Oncol 22 (2003) 565
35. Rodríguez J., Caballero M.D., Gutiérrez A., et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14 (2003) 1768-1775
36. Rodríguez J., Conde E., Gutiérrez A., et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18 (2007) 652-657
37. Kyriakou C., Canals C., Goldstone A., et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 26 (2008) 218-224
38. Rodríguez J., Conde E., Gutiérrez A., et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79 (2007) 32-38
39. Mercadal S., Briones J., Xicoy B., et al., Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB). Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19 (2008) 958-963
40. Reimer P., Rüdiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27 (2009) 106-113
41. Dearden C.E., Matutes E., Cazin B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98 (2001) 1721-1726
42. Lundin J., Hagberg H., Repp R., et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101 (2003) 4267-4272
43. Gallamini A., Zaja F., Patti C., et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110 (2007) 2316-2323
44. Kim J.G., Sohn S.K., Chae Y.S., et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58 (2006) 35-39
45. Arkenau H.T., Chong G., Cunningham D., et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92 (2007) 271-272
46. Tse E., Leung R., Khong P.L., Lau W.H., and Kwong Y.L. Non-nasal natural killer cell lymphoma: not non-nasal after all. Ann Hematol 88 (2009) 185-187
47. You J.Y., Chi K.H., Yang M.H., et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 15 (2004) 618-625
48. Cheung M.M., Chan J.K., Lau W.H., Ngan R.K., and Foo W.W. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54 (2002) 182-190
49. Kwong Y.L., Chan A.C., Liang R., et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 97 (1997) 821-829
50. Kim W.S., Song S.Y., Ahn Y.C., et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?. Ann Oncol 12 (2001) 349-352
51. Cheung M.M., Chan J.K., and Wong K.F. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 40 (2003) 221-232
52. Egashira M., Kawamata N., Sugimoto K., Kaneko T., and Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 93 (1999) 599-606
53. Chim C.S., Ma S.Y., Au W.Y., et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103 (2004) 216-221
54. Lee J., Suh C., Park Y.H., et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24 (2006) 612-618
55. Kwong Y.L. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant (2009) 10.1038/bmt.2009.239 published online Sept 21.
56. Au W.Y., Lie A.K., Liang R., et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 14 (2003) 1673-1676
57. Suzuki R., Suzumiya J., Nakamura S., et al., NK-cell Tumor Study Group. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 37 (2006) 425-431
58. Murashige N., Kami M., Kishi Y., et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 130 (2005) 561-567
59. Matsumoto Y., Nomura K., Kanda-Akano Y., et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 44 (2003) 879-882
60. Yong W., Zheng W., Zhang Y., et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78 (2003) 163-167
61. Yamaguchi M., Suzuki R., Kwong Y.L., et al. Phase 1 study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99 (2008) 1016-1020